Ascendis Pharma A/S (ASND) to Announce Earnings on Thursday

Posted by Stanley Muller on Aug 4th, 2026

Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) is anticipated to announce its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of $1.71 per share and revenue of $376.75 million for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:30 PM ET.

Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.11. The company had revenue of $285.45 million during the quarter, compared to the consensus estimate of $362.47 million. On average, analysts expect Ascendis Pharma A/S to post $4 EPS for the current fiscal year and $12 EPS for the next fiscal year.

Ascendis Pharma A/S Stock Down 0.2%

NASDAQ:ASND opened at $243.45 on Tuesday. The company has a market cap of $15.19 billion, a price-to-earnings ratio of 28.08 and a beta of 0.39. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.72 and a current ratio of 1.00. The stock’s fifty day moving average price is $244.88 and its two-hundred day moving average price is $235.29. Ascendis Pharma A/S has a 52-week low of $173.33 and a 52-week high of $282.15.

Wall Street Analysts Forecast Growth

ASND has been the subject of a number of recent research reports. Oppenheimer restated an “outperform” rating on shares of Ascendis Pharma A/S in a research report on Tuesday, June 9th. Wall Street Zen lowered Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research report on Saturday, July 18th. Weiss Ratings raised Ascendis Pharma A/S from a “sell (d)” rating to a “hold (c)” rating in a report on Wednesday, July 15th. Morgan Stanley upped their target price on shares of Ascendis Pharma A/S from $256.00 to $275.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. Finally, Royal Bank Of Canada lifted their price target on shares of Ascendis Pharma A/S from $275.00 to $280.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 7th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, Ascendis Pharma A/S presently has an average rating of “Buy” and a consensus target price of $296.72.

Get Our Latest Research Report on ASND

Insiders Place Their Bets

In other Ascendis Pharma A/S news, insider Flemming Steen Jensen sold 19,460 shares of the stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $238.49, for a total value of $4,641,015.40. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Jean Jacques Bienaime bought 400 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The shares were bought at an average price of $237.80 per share, with a total value of $95,120.00. Following the completion of the transaction, the director directly owned 400 shares in the company, valued at approximately $95,120. This trade represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. 40.00% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of ASND. Graham Capital Management L.P. bought a new position in Ascendis Pharma A/S in the fourth quarter valued at approximately $228,000. HRT Financial LP bought a new stake in shares of Ascendis Pharma A/S during the fourth quarter worth $239,000. State of Wyoming acquired a new stake in shares of Ascendis Pharma A/S during the fourth quarter worth $175,000. PharVision Advisers LLC acquired a new stake in shares of Ascendis Pharma A/S during the third quarter worth $233,000. Finally, Certuity LLC bought a new stake in Ascendis Pharma A/S in the 3rd quarter valued at $220,000.

Ascendis Pharma A/S Company Profile

(Get Free Report)

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.